<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23544">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124213</url>
  </required_header>
  <id_info>
    <org_study_id>B7441005</org_study_id>
    <nct_id>NCT02124213</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers</brief_title>
  <acronym>PET</acronym>
  <official_title>Open Label Adaptive Design Study to Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [11C]SCH23390 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate D1 Receptor Occupancy (RO) following a single dose of PF-06412562
      In healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>PF-06142562 plasma exposure and RO in the striatum</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using Positron Emission Tomography and a radiotracer [11C]SCH23390, the PF-06142562 plasma exposure and RO in the striatum (average of caudate and putamen) will be measured in  healthy male subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile from time zero to the last plasma measurement at 4 hours (AUC0-4)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma concentration over 4 hours (Cav,0-4)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohor 1 - 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 ( adaptive dose, optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 ( adaptive dose, optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg PF-06412562</intervention_name>
    <description>Subject will receive a single dose of 30 mg PF-06412562</description>
    <arm_group_label>Cohor 1 - 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562</intervention_name>
    <description>The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.</description>
    <arm_group_label>Cohort 2 ( adaptive dose, optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562</intervention_name>
    <description>The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
This Cohort is optional.</description>
    <arm_group_label>Cohort 3 ( adaptive dose, optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Male Volunteers

        Exclusion Criteria:

        Evidence or history of clinically significant hepatic, renal, cardiovascular, endocrine,
        hematologic, gastrointestinal, pulmonary, neurologic, oncologic, psychiatric, or allergic
        disease Any condition possibly affecting drug absorption A positive urine drug screen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7441005&amp;StudyName=A%20Study%20To%20Evaluate%20D1%20Receptor%20Occupancy%20%28RO%29%20Following%20Single%20Dose%20of%20PF-06412562%20In%20Healthy%20Male%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Receptor Occupancy</keyword>
  <keyword>PET</keyword>
  <keyword>D1 Receptor Agonist</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
